<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645968</url>
  </required_header>
  <id_info>
    <org_study_id>ILD Patient Registry</org_study_id>
    <nct_id>NCT02645968</nct_id>
  </id_info>
  <brief_title>Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING</brief_title>
  <acronym>EXCITING</acronym>
  <official_title>Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Lung Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut für Lungenforschung e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Respiratory Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WATL e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bundesverband der Pneumologen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lungenfibrose e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sacura GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syneed Medidata GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect valid data from all forms of health care on the
      incidence, prevalence, the regional distribution, characteristics, management and outcomes of
      different ILDs under clinical practice conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interstitial lung diseases (ILD) are a heterogeneous group of more than 200 entities that can
      be idiopathic or as a result of other diseases and/or treatments. All forms of ILD are
      considered to be seldom or very seldom (and most of them are so-called &quot;orphan&quot; diseases), in
      their entirety they seem to represent an epidemiological burden, which should not be
      underestimated, e.g. as &quot;normal&quot; symptoms of the elderly.

      The knowledge about the epidemiology of ILDs is very limited, in general and in Germany in
      particular. For Germany no current, valid and comprehensive population-based data on ILDs
      exist because no appropriate ILD classification was available for a long time. The
      epidemiological data, which were collected before the introduction of the current
      classification of ILD according to the ATS/ERS consensus and before HRCT was considered the
      diagnostic gold standard, are not very reliable. Furthermore systemic investigations relating
      to the development of an ILD of risk groups, such as patients undergoing radio- or
      chemotherapy or patients with connective tissue disease, are restricted.

      Thus, only little is known about costs associated with ILDs. Idiopathic Pulmonary Fibrosis
      (IPF), as one of the disease entities, was shown to be associated with high healthcare
      utilization and costs in England and the USA, as in many cases lung transplantation is the
      only therapeutic option and also new pharmaceutical treatments are costly. But there is a
      lack of data on healthcare utilization and financial consequences of other ILD than IPF in
      Germany. Therefore, this registry will provide an important database for health economics and
      health services research questions.

      Against this background, this multi-centre, non interventional prospective observational
      disease and outcomes registry for ILD aims to collect valid data from all forms of health
      care on the incidence, prevalence, the regional distribution, characteristics, management and
      outcomes of different ILDs under clinical practice conditions. In detail, demographic data
      such as gender, age, country of birth, place of residence; disease related data such as
      subtype of ILD, treatment center, diagnostic procedures (e.g. HRCT, lung biopsy, pulmonary
      function tests); risk factors (e.g. smoking status, profession, familial ILD);
      co-morbidities; ILD management as analysed by the kind and frequency of pharmacological and
      non-pharmacological therapies; outcome; and consumption of resources will be recorded.
      Therefore, this registry will allow obtaining a comprehensive and current epidemiologic
      report for ILDs in Germany and can be particularly helpful in uncovering correlations between
      risk exposure and disease development.

      This study, with up to 100 sites, initially focused on the federal states Baden-Wuerttemberg
      and Hesse, is planned for a minimum of 5 years and 600 patients should be enrolled as part of
      the study a screening/baseline visit, on which the Informed Consent Form will be signed, and
      every 6 months regularly updates/phone contacts will be performed.

      Following quality procedures are applicable for this registry:

        -  Quality assurance plan that addresses data validation and registry procedures, including
           any plans for site monitoring and auditing.

        -  Data checks to compare data entered into the registry against predefined rules for range
           or consistency with other data fields in the registry.

        -  Source data verification to assess the accuracy, completeness, or representativeness of
           registry data by comparing the data to external data sources (e.g., medical records,
           paper or electronic case report forms, or interactive voice response systems).

        -  Standard Operating Procedures to address registry operations and analysis activities,
           such as patient recruitment, data collection, data management, data analysis, reporting
           for adverse events, and change management.

        -  Sample size assessment to specify the number of participants or participant years
           necessary to demonstrate an effect.

        -  Plan for missing data to address situations where variables are reported as missing,
           unavailable, &quot;non-reported,&quot; uninterpretable, or considered missing because of data
           inconsistency or out-of-range results

        -  Statistical analysis plan describing the analytical principles and statistical
           techniques to be employed in order to address the primary and secondary objectives, as
           specified in the study protocol or plan.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Determination of characteristics, management and outcomes of patients with different ILDs under clinical practice conditions.</measure>
    <time_frame>Six month interval over 5 years</time_frame>
    <description>(disease-related) characteristics of ILD patients
diagnostic procedures for the identification of ILDs
the clinical management of different (sub) types of ILD under clinical practice
the outcome of different types of ILDs and of ILD related therapies from all forms of health care facilities</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Interstitial Lung Disease (ILD)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        ILD patients from all forms of health care
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Able to read and understand the scope and nature of data collection

          -  Aged ≥ 18 at time of informed consent

          -  Patients diagnosed with interstitial lung disease (ILD). Patients with suspicion on
             interstitial lung disease cannot be included into the registry, only after consens
             diagnosis of an ILD. This is also the case for patients with not classifiable ILDs.

        Subjects with the following subtypes of ILD will be enrolled:

          1. Idiopathic interstitial pneumonia (IIPs)

               -  Idiopathic pulmonary fibrosis (IPF)

               -  Non-specific interstitial pneumonia (NSIP)

               -  Desquamative interstitial pneumonia (DIP)

               -  Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)

               -  Cryptogenic organizing pneumonia (COP)

               -  Lymphocytic interstitial pneumonia (LIP)

               -  Acute interstitial pneumonia (AIP)

               -  Rare forms of IIPs (e.g. pleuropulmonary fibroelastosis)

               -  Not classifiable IIP

          2. Granulomatous lung disease

               -  Sarcoidosis

               -  Berylliosis

               -  Other (e.g. involvement in chronic inflammatory liver and gut diseases, except
                  EAA)

          3. Hypersensitivity pneumonitis (exogen allergic alveolitis (EAA))

               -  Farmer's lung

               -  Bird keepers' lung disease

               -  Origin unknown

               -  Other

          4. Rheumatic and connective tissue diseases with pulmonary involvement like:

               -  Connective tissue disease (subtype)

               -  Vasculitis

               -  Rheumatoid arthritis

          5. Pneumoconiosis

               -  Asbestosis

               -  Silicosis

               -  Other

          6. Other forms

               -  Pulmonary lymphangioleiomyomatosis

               -  Pulmonary Langerhans' cell histiocytosis

               -  Pulmonary alveolar proteinosis

               -  Eosinophilic pneumonia

               -  Post-ARDS Fibrosis

          7. Drug-related

          8. Radiotherapy associated

          9. Fibrosis in emphysema patients without signs of other ILDs (i.e. smoking related
             interstitial fibrosis or &quot;emphysemasclerosis&quot;)

         10. Others

         11. Not classifiable

        Furthermore for each subtype it will be queried, if a diagnosis of concomitant emphysema in
        ILD was made.

        Exclusion Criteria:

        - Patients without interstitial lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kreuter, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for interstitial and rare lung diseases, Pneumology and Respiratory Medicine, Thorax Clinic, University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lungenärztliche Gemeinschaftspraxis Dr. Storz / Dr. Prettner</name>
      <address>
        <city>Böblingen</city>
        <state>Baden-Württemberg</state>
        <zip>71034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg, Abteilung Pneumologie und Beatmungsmedizin</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitsverbund Landeskreis Konstanz, Krankenhausbetriebsgesellschaft Konstanz</name>
      <address>
        <city>Konstanz</city>
        <state>Baden-Württemberg</state>
        <zip>78464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologische Praxis im Zentrum - PiZ, Dr. med. Hans-Paul Eulenbruch und Dr. med. Alexander Rupp</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Klinik für Allgemeine Innere Medizin, Gastroenterologie, Hepatologie und Infektiologie, Pneumologie</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenpraxis Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Zentrum</name>
      <address>
        <city>Wiesloch</city>
        <state>Baden-Württemberg</state>
        <zip>69168</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikverbund Kempten-Oberallgäu, Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin</name>
      <address>
        <city>Immenstadt</city>
        <state>Bayern</state>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologische Gemeinschaftspraxis Fulda Dres. Wiederhold, Schratz, Wissner</name>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG, Medizinische Klinik V - Pneumologie</name>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenfachklinik Immenhausen</name>
      <address>
        <city>Immenhausen</city>
        <state>Hessen</state>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Medizinische Klinik I</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Malteser Bonn gem. GmbH, Malteser Lungen- und Allergiezentrum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Rheinhausen GmbH</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47228</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik - Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinkum Gütersloh, Medizinische Klink III, Pneumologie, Schlaf- und Beatmungsmedizin, Infektiologie und Allgemeine Innere Medizin</name>
      <address>
        <city>Gütersloh</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33332</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital GmbH</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50668</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Hildegardis, Klinik für Pneumologie und Beatmungsmedizin</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholische Kranken- und Pflegeeinrichtung Leverkusen GmbH, St. Remigius Krankenhaus Opladen</name>
      <address>
        <city>Leverkusen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51379</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>framol-med GmbH, Pneumoglische Gemeinschaftspraxis Rheine</name>
      <address>
        <city>Rheine</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Bethanien gGmbH, Klinik für Pneumologie und Allergologie, Zentrum für Schlaf- und Beatmungsmedizin</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Demedts M, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Poletti V, Verbeken EK, Thomeer MJ, Kokkarinen J, Dalphin JC, Taylor AN. Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl. 2001 Sep;32:2s-16s. Review.</citation>
    <PMID>11816822</PMID>
  </reference>
  <reference>
    <citation>Akgün KM, Crothers K, Pisani M. Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci. 2012 Mar;67(3):276-91. doi: 10.1093/gerona/glr251. Epub 2012 Feb 15. Review.</citation>
    <PMID>22337938</PMID>
  </reference>
  <reference>
    <citation>Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol. 2012;2012:415272. doi: 10.5402/2012/415272. Epub 2012 Mar 27.</citation>
    <PMID>22567412</PMID>
  </reference>
  <reference>
    <citation>Gunnarsson R, Aaløkken TM, Molberg Ø, Lund MB, Mynarek GK, Lexberg AS, Time K, Dhainaut AS, Bertelsen LT, Palm O, Irgens K, Becker-Merok A, Nordeide JL, Johnsen V, Pedersen S, Prøven A, Garabet LS, Gran JT. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012 Dec;71(12):1966-72. doi: 10.1136/annrheumdis-2011-201253. Epub 2012 May 1.</citation>
    <PMID>22550317</PMID>
  </reference>
  <reference>
    <citation>Hallowell RW, Reed RM, Fraig M, Horton MR, Girgis RE. Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Pulm Circ. 2012 Jan-Mar;2(1):101-6. doi: 10.4103/2045-8932.94842.</citation>
    <PMID>22558525</PMID>
  </reference>
  <reference>
    <citation>Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol. 2012 Mar;5(2):219-27. doi: 10.1586/ecp.12.9. Review.</citation>
    <PMID>22390563</PMID>
  </reference>
  <reference>
    <citation>Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:143637. doi: 10.1155/2012/143637. Epub 2012 May 10.</citation>
    <PMID>22655194</PMID>
  </reference>
  <reference>
    <citation>Amar RK, Jick SS, Rosenberg D, Maher TM, Meier CR. Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis. Respirology. 2012 Jul;17(5):861-8. doi: 10.1111/j.1440-1843.2012.02187.x.</citation>
    <PMID>22563933</PMID>
  </reference>
  <reference>
    <citation>King TE Jr. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011 Mar 10;364(10):968-70. doi: 10.1056/NEJMe1013966.</citation>
    <PMID>21388315</PMID>
  </reference>
  <reference>
    <citation>Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, Austin JH, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med. 2009 Sep 1;180(5):407-14. doi: 10.1164/rccm.200812-1966OC. Epub 2009 Jun 19.</citation>
    <PMID>19542480</PMID>
  </reference>
  <reference>
    <citation>Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.</citation>
    <PMID>21471066</PMID>
  </reference>
  <reference>
    <citation>Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012 Jun 1;185(11):1147-53. doi: 10.1164/rccm.201108-1420PP. Epub 2012 Feb 23. Review.</citation>
    <PMID>22366047</PMID>
  </reference>
  <reference>
    <citation>Lynge E. Implication for epidemiology of disease registers. Public Health Rev. 1993-1994;21(3-4):263-70. Review.</citation>
    <PMID>8047653</PMID>
  </reference>
  <reference>
    <citation>American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. Review. Erratum in: Am J Respir Crit Care Med2002 Aug 1;166(3):426.</citation>
    <PMID>11790668</PMID>
  </reference>
  <reference>
    <citation>Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002 May;19(5):794-6.</citation>
    <PMID>12030715</PMID>
  </reference>
  <reference>
    <citation>Kreuter M, Herth FJ, Wacker M, Leidl R, Hellmann A, Pfeifer M, Behr J, Witt S, Kauschka D, Mall M, Günther A, Markart P. Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry--The EXCITING-ILD Registry. Biomed Res Int. 2015;2015:123876. doi: 10.1155/2015/123876. Epub 2015 Nov 10.</citation>
    <PMID>26640781</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Michael Kreuter</investigator_full_name>
    <investigator_title>Head of Center for interstitial and rare lung diseases</investigator_title>
  </responsible_party>
  <keyword>Pneumology</keyword>
  <keyword>Registry</keyword>
  <keyword>EXCITING</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>ILD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

